An older adult holds an unmarked injection pen at a kitchen table beside an open carton, with a bathroom scale visible through a doorway.
Lifestyle 8 min read

Stopping Wegovy May Bring Back Lost Weight, With Years Still Uncharted

Two semaglutide studies suggest weight may return within a year of stopping Wegovy. They leave open how much returns over time and what happens to heart risk.

DISCLAIMER

This article is for informational purposes only and does not constitute medical advice. The statements in this article have not been evaluated by the FDA. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Consult your physician before starting any supplement or health protocol.

At week 20 of the STEP 4 trial, 803 adults who had completed an initial course of injectable semaglutide were randomly assigned to keep receiving it or to receive a look-alike placebo. For anyone weighing a refill against its cost, side effects, or the prospect of years of treatment, the split foreshadowed a practical risk: over the next 48 weeks, average weight rose in the group that switched and fell in the group that continued. STEP 4 randomized trial

The trial that changed what was in the injection

Everyone who entered STEP 4 started on semaglutide, the active ingredient in Wegovy. The 803 people who reached randomization had lost an average of 10.6% of their starting weight during those first 20 weeks. After randomization, both groups continued receiving lifestyle support. By week 68, the group still receiving semaglutide had lost an estimated additional 7.9% of its week-20 weight. The group switched to placebo had gained an estimated 6.9% relative to that same milestone. The estimated gap between the groups was 14.8 percentage points. STEP 4 randomized trial

Week 20 matters when reading those percentages. A person who went from 100 kilograms to 90 kilograms and then gained 6.9% would finish a little above 96 kilograms. That example illustrates how a substantial rebound can leave someone below their original weight. It also shows why adding or subtracting the published percentages directly can give the wrong impression. The first percentage starts from enrollment weight, while the second starts from a lower weight at randomization. STEP 4 randomized trial

Random assignment makes the difference between the groups more informative than a comparison of patients who independently chose to stop or continue. In routine care, the decision to stop can coincide with changes in insurance, side effects, or a shift in health. Those factors could also influence what happens afterward. The trial made the switch by chance and kept lifestyle support in both arms, making it more plausible that removing semaglutide contributed to the divergence in weight. STEP 4 randomized trial

The 20-week lead-in also narrows whom the result describes. Of the 902 people who started that phase, 803 reached randomization. In practice, someone who stops within a few weeks because they cannot tolerate the medication may have had less time to lose weight and could have a different trajectory. STEP 4 provides its clearest estimate for adults who made it through the initial treatment period under trial conditions. STEP 4 randomized trial

Where the two-thirds figure comes from

A separate team followed a subset of participants from STEP 1, a trial in adults with overweight or obesity and without diabetes. The main study lasted 68 weeks. When that phase ended, trial medication and structured lifestyle support both stopped. In the 327-person extension, those originally assigned semaglutide had lost an average of 17.3% of their starting weight by week 68. During the following year, they regained 11.6 percentage points of starting weight on average and finished 5.6% below their starting weight. Rounding in the reported averages accounts for the small difference when subtracting the figures. STEP 1 extension

The widely cited two-thirds figure compares the amount regained with the amount previously lost in that group. It describes the group’s average, so it offers limited guidance on how much one person might regain. Selection also matters. The extension drew from a subset of sites and included people who had completed the main trial. Its authors described the follow-up analyses as exploratory. STEP 1 extension

Several cardiometabolic measures in the extension moved back toward their starting levels after treatment ended. That may matter to a reader who tracks blood pressure or blood sugar alongside weight. The study followed these measurements over a year, so their movement gives a picture of changing risk factors. Estimating how many people would later have a heart attack or stroke would require follow-up designed around those events. STEP 1 extension

The two STEP studies capture different versions of stopping. STEP 4 switched treatment after 20 weeks and continued lifestyle support. The STEP 1 extension started after 68 weeks, when both the study drug and structured support ended. The studies also used different starting points for reporting regain. Their agreement about the direction of weight change makes the possibility of regain harder to dismiss. Their different designs leave open how much the duration of treatment or ongoing support might change its size. STEP 4 randomized trial and STEP 1 extension

Why appetite may change again

Semaglutide activates the GLP-1 receptor. The U.S. prescribing information describes reduced calorie intake as an effect likely mediated by appetite. In everyday terms, an intervention that makes it easier to eat less may change the experience of getting through meals and the hours between them. As the drug clears after stopping, its effect on appetite may fade. That offers a plausible route from treatment withdrawal to weight regain, even if someone intends to keep the same eating habits. FDA prescribing information

The drug also takes time to clear. The prescribing information puts semaglutide’s elimination half-life at roughly one week. In pharmacology, a half-life describes how long it takes for the amount of drug in the body to fall by half under specified conditions. It supplies a rough time scale for the fading drug effect. The day someone feels hungrier, or first sees a change on the scale, can vary and cannot be read off that number. FDA prescribing information

The withdrawal trials are clearer on the scale than on the experience of appetite. Their headline estimates compare body weight at scheduled visits. Those measurements cannot tell whether each person ate larger meals, ate more often, or experienced changes in physical activity or energy expenditure. Someone may experience more hunger before a change in weight becomes apparent. Someone else could see a weight change without recalling a specific shift in appetite. These are plausible paths, and the trial averages do not establish how common either path was. STEP 4 randomized trial and STEP 1 extension

What the heart trial can tell you

The SELECT trial gives a separate reason the refill question may matter for some older adults. It enrolled 17,604 people aged 45 or older who had established cardiovascular disease and overweight or obesity, without diabetes. During an average follow-up of about 40 months, 6.5% of those assigned semaglutide and 8.0% of those assigned placebo experienced the study’s main composite outcome. That outcome counted cardiovascular death, nonfatal heart attack, or nonfatal stroke. The observed difference of 1.5 percentage points amounts to about 15 fewer people per 1,000 experiencing a first such event during follow-up. SELECT cardiovascular outcomes trial

The published hazard ratio of 0.80 describes the relative difference in the rate of those first events over follow-up. The 6.5% and 8.0% figures show the absolute proportions observed in the groups. Those two views help put the benefit in context for people who resemble the trial participants. Someone who has never had cardiovascular disease may start with a different risk of these events, so the same number of events prevented should not be assumed. SELECT cardiovascular outcomes trial

SELECT also recorded adverse events that led participants to stop the assigned trial product. They occurred in 16.6% of those assigned semaglutide and 8.2% of those assigned placebo. The researchers analyzed cardiovascular outcomes by original assignment, including participants who stopped. That design helps answer what happened after assignment to the treatment strategy. It cannot isolate what happened to cardiovascular risk specifically because someone discontinued the medicine, since SELECT did not randomly assign people to stop after a period on semaglutide. SELECT cardiovascular outcomes trial

This is where the weight graph reaches its limit. The 6.9% weight increase after switching to placebo in STEP 4 supplies no estimate of how quickly cardiovascular risk might change after a final injection. A study addressing that question would need a comparable group of people who continued treatment and enough follow-up to count heart attacks and strokes directly. The distinction may matter especially to someone taking Wegovy after a cardiovascular event, who has a different treatment goal from someone following weight alone. STEP 4 randomized trial and SELECT cardiovascular outcomes trial

The unanswered years after the last injection

One year is long enough for the STEP 1 extension to show that substantial regain may occur. It is too short to reveal where weight might settle over several years. The average curve appeared to rise more slowly toward the end of that extension, and the investigators left open whether this represented a lasting plateau. Extending that last stretch of the curve into a prediction would assume that subsequent years will resemble its final months. STEP 1 extension

A pharmacy interruption, a planned taper, and a switch to another medication are distinct situations. The STEP studies examined defined withdrawals and tracked what happened afterward under their own protocols. They did not randomize people among those three paths. A credible comparison of tapering with a direct stop would begin with people who had spent a similar time on treatment, keep follow-up support comparable, and track how often participants restarted or changed medication. Otherwise, an apparently better result might reflect who could keep filling a prescription or who received more follow-up. STEP 4 randomized trial and STEP 1 extension

For an older adult, the unanswered question can also extend beyond total body weight. A scale combines fat, muscle, and other tissue into one reading. It cannot show whether a person can climb stairs, carry groceries, or walk the same distance with fewer breaks after losing and regaining weight. The withdrawal results cited here give no direct estimate of those changes. A longer follow-up designed around daily life could measure strength and walking performance alongside body composition, especially among adults who entered treatment with limited mobility. STEP 4 randomized trial and STEP 1 extension

What these studies offer is a time frame for the risk a person may face at a refill decision. The weight loss observed during treatment can partly reverse within roughly a year after stopping, including when lifestyle support continues. The amount that returns over several years, the effect of other ways to stop, and the course of cardiovascular risk after withdrawal remain separate questions with no answer in these trials. STEP 4 randomized trial, STEP 1 extension, and SELECT cardiovascular outcomes trial

Frequently asked questions

Does everyone regain two-thirds of the weight they lost?

No. That figure was an average from one extension study. Individual results may vary. STEP 1 extension

Can weight return while lifestyle support continues?

Yes. Average weight rose after the switch to placebo in STEP 4, where both groups continued receiving lifestyle support. STEP 4 randomized trial

Does Wegovy’s heart benefit persist after stopping?

The SELECT trial leaves that uncertain. It tested starting semaglutide versus placebo and did not randomize people to stop after treatment. SELECT cardiovascular outcomes trial


This article summarises published research and is not medical advice. Consult your healthcare provider before changing your routine.

Frequently Asked Questions

Does everyone regain two-thirds of the weight they lost?
No. That figure was an average from one extension study. Individual results may vary.
Can weight return while lifestyle support continues?
Yes. Average weight rose after the switch to placebo in STEP 4, where both groups continued receiving lifestyle support.
Does Wegovy’s heart benefit persist after stopping?
The SELECT trial leaves that uncertain. It tested starting semaglutide versus placebo and did not randomize people to stop after treatment.

Sources

  1. Rubino et al., STEP 4 randomized withdrawal trial, JAMA(2026)
  2. Wilding et al., STEP 1 off-treatment extension, Diabetes, Obesity and Metabolism(2026)
  3. Lincoff et al., SELECT cardiovascular outcomes trial, New England Journal of Medicine(2026)
  4. U.S. Food and Drug Administration, Wegovy prescribing information(2026)
Wegovy semaglutide weight regain clinical trials cardiovascular risk

Stay Updated on Longevity Science

Weekly research digests. No spam, unsubscribe anytime.

Subscribe

Related Articles